Magazine Article | March 8, 2017

Companies To Watch: Edge Therapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.

Edge Therapeutics is a public company in Phase 3 development with a sustained-release form of nimodipine, coded EG-1962, to prevent delayed cerebral ischemia (DCI), a common fatal or debilitating complication of aneurysmal subarachnoid hemorrhage (aSAH), or ruptured brain aneurysm.